GKOS — GLAUKOS Corp
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1192448 ·
Last close
$161.29
Market Cap
$9.51B
52W High
$191.62
52W Low
$73.16
ADV30
885,575
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 185,610,000 | 151,594,000 | -15,767,000 | -18,377,000 | 920,521,000 | 114,485,000 | 238,035,000 |
| Mar 2026 | 150,571,000 | 117,232,000 | -19,856,000 | -19,783,000 | 893,326,000 | 104,249,000 | 222,398,000 |
| Dec 2025 | 143,121,000 | -1,517,000 | -139,868,000 | -133,657,000 | 893,487,000 | 90,813,000 | 237,332,000 |
| Sep 2025 | 133,537,000 | 104,706,000 | -16,365,000 | -16,231,000 | 999,378,000 | 98,246,000 | 229,835,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-950,000
Investing CF
$-14,685,000
Financing CF
$24,451,000
CapEx
$-27,853,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.25
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-971,290,000
Inventory
$59,306,000
Receivables
$138,900,000
ST Investments
$171,741,000
EBIT TTM
$-187,928,000
Pretax Income TTM
$-192,833,000
Interest Exp TTM
$4,905,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$612,838,976
EBITDA
$-37,025,000
Free Cash Flow
$15,456,250
Enterprise Value
$9,681,758,208
Total Cash
$286,225,984
Total Debt
$107,604,000
Shares Out
58,983,937
Trailing EPS
$-3.28
Book Value
$11.60
ROE
-26.0%
ROA
-5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 507,442,000 | -199,600,000 | -187,691,000 | 893,487,000 | 237,332,000 | 656,155,000 | -14,789,000 |
| Dec 2024 | 383,481,000 | -108,137,000 | -146,372,000 | 974,756,000 | 207,825,000 | 766,931,000 | -61,318,000 |
| Dec 2023 | 314,711,000 | -123,700,000 | -134,661,000 | 940,414,000 | 478,648,000 | 461,766,000 | -57,758,000 |
| Dec 2022 | 282,862,000 | -102,313,000 | -99,195,000 | 1,002,383,000 | 472,378,000 | 530,005,000 | -33,083,000 |
TTM Snapshot
Revenues TTM
$551,349,000
NetIncome TTM
$-189,328,000
OpCashFlow TTM
—
Assets (Latest)
$893,326,000
Forward EPS
$0.50
Max Pain — expiry 2026-10-16
max pain strike: $160.00 · spot: $165.69 · call oi: 3,203 · put oi: 5,090
Expected Move to 2026-10-16:
±$8.90
(5.37%) —
implied range
$156.79 –
$174.59
· ATM straddle on $165.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PODD | INSULET CORP | $9.33B | $134.47 | — |
| ALGN | ALIGN TECHNOLOGY INC | $10.02B | $141.03 | — |
| SNNUF | SMITH & NEPHEW PLC | $10.74B | $12.83 | — |
| GMED | GLOBUS MEDICAL INC | $8.20B | $73.33 | — |
| SNN | SMITH & NEPHEW PLC | $11.28B | $26.96 | — |
News headlines (Yahoo Finance, 1h cache)
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
2026-10-09 15:15 · Yahoo
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
2026-10-08 16:49 · Yahoo
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
2026-10-08 11:00 · Yahoo
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
2026-10-07 20:05 · Yahoo
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
2026-09-24 15:46 · Yahoo
Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus
2026-09-23 11:00 · Yahoo
Glaukos (GKOS) Stock Looks Fully Priced Against Its Sales Growth Story
2026-09-23 09:13 · Yahoo
Glaukos (GKOS), Why Is It Back In The Spotlight?
2026-09-23 08:16 · Yahoo
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
2026-08-28 15:30 · Yahoo
Glaukos Announces Participation in Wells Fargo Healthcare Conference
2026-08-19 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.